At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk ...

Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from 2022 to 2023. Although spending for certain GLP-1 RAs increased ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...

The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...

GLP-1 receptor agonists are peptide-based drugs used for managing diabetes and for weight loss, but these treatments have had shortages recently. Now, through a process called in vivo antibody ...

G-protein coupled receptors regulate hormone secretions in the pancreas. Learn how the complex signaling features ... such as glucagon-like peptide-1, free fatty acids, and catecholamines.

New research shows GLP-1 receptor agonists may protect patients with type 2 diabetes from deadly blood cancers—beyond just managing blood sugar. Glucagon-like peptide 1 (GLP-1, 7-36) molecule ...

Study: Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study. Image Credit: azimmytws / Shutterstock.com A ...

Liraglutide is a peptide that has gained significant attention in scientific research due to its structural similarity to ...